Introduction
Co-stimulation plays an important role in the outcome of T cell activation. When T cell antigen receptors (TCR) interact with antigen-major histocompatibility complex (MHC) in the absence of co-receptor engagement, T cells become non-functional, a state usually referred to as anergy. On the other hand, if T cells receive co-stimulation during antigen-TCR interaction, T cells become functionally activated, and the outcomes are proliferation and the generation of effector populations. CD28 is one important coreceptor, which regulates T cell proliferation and survival. The ability to costimulate the production of interleukin-2 (IL-2) and induce Bcl-X L gene expression comprise important roles that CD28 signaling plays in T cell activation [1] [2] [3] . Besides IL-2, CD28 costimulation also induces other important cytokine genes including interferon-(IFN-), granulocyte-macrophage-colony-stimulating factor (GMCSF), and interleukin-8 (IL-8) 4 .
These effects of CD28 ligation on cytokine gene expression have been shown to occur by both transcriptional and post-transcriptional (mRNA stability) mechanisms [5] [6] [7] .
Although significant work has been done to elucidate the signaling pathways involved in CD28 co-stimulation, a complete understanding of these pathways is yet to be achieved. It is not clear whether CD28 engagement generates a unique signaling pathway that complements TCR signaling, or whether CD28 signaling potentiates TCR-mediated signaling to decrease the threshold of T cell activation 8, 9 . It has been proposed that CD28 signaling has two components: one is calcium-dependent and sensitive to cyclosporin A (CsA) similar to TCR signaling, and the other one is calcium-independent only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From and resistant to CsA 10 . One of the first signaling molecules directly involved with activated CD28 was phosphatidylinositol 3-kinase (PI3-K), although the role of PI3-K in CD28 signaling remains controversial [11] [12] [13] . Recently, it has been shown that transgenic mice or primary T cells carrying a CD28 mutant that lacks ability to bind PI3-K were capable of distinguishing proliferative signals from survival signals. These cells were unable to express Bcl-X L , while their ability to proliferate and to produce IL-2 were intact [14] [15] [16] . Previously it has been shown that signals originating from TCR and CD28
converge on the activation of jun N-terminal kinase (JNK) 17 , but recently, Vav-1, a proto-oncogene product, has been shown to be the point of integration for the two activation signals, and lies upstream to the JNK signaling pathway [18] [19] [20] [21] .
Rapamycin is a macrolide antibiotic with potent immunosuppressive properties.
Rapamycin is structurally related to the well-known immunosuppressant FK506, and binds to the same intracellular receptor FKBP12 (FK506-binding protein) 22 .
Interestingly, although both FK506 and rapamycin bind to the same intracellular receptor, the principal target proteins are different for these two compounds. Whereas FK506-FKBP12 inhibits the serine-threonine phosphatase calcineurin, rapamycin-FKBP12
inhibits the serine-threonine kinase mTOR (mammalian target of rapamycin)/FRAP (FKBP12-rapamycin associated protein) [23] [24] [25] [26] [27] [28] . Rapamycin treatment has been shown to cause G1 arrest in a variety of cell types including T cells 29, 30 . The inhibition of T cell proliferation is primarily due to the blockage of interleukin-2 (IL-2) signaling 31,32 , supporting the clinical use of rapamycin as an immunosuppressant 33 . It has been well established that mTOR is a key regulator of translation 34 , and two of the most important only.
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Hypophosphorylated 4EBP-1 binds to eIF4E and prevents it from forming a productive mRNA cap binding complex, whereas phosphorylation of 4EBP-1 abrogates this interaction 36 . Another target of mTOR is p70 s6k , which phosphorylates S6 protein of the 40S ribosome, and is important in regulating the translation of an essential family of mRNAs that contain an oligopyrimidine tract at their transcription start site 37, 38 .
Depending on the primary stimulation, CD28 can initiate multiple pathways. One of these pathways is CsA-resistant, and has been suggested to be involved in graft-versushost disease (GVHD) during allogenic bone marrow transplantation 39 . Surprisingly, very little is known about this pathway. In this report we demonstrate the effect of rapamycin on the CsA-resistant pathway of CD28 co-stimulation. Rapamycin treatment inhibited the production of IL-2 by activated human peripheral blood T cells. The inhibition of IL-2 production was mainly due to the blockage of the CsA-resistant pathway, since rapamycin had no effect on the CsA-sensitive pathway. The mechanism of the effect of rapamycin on the IL-2 production was observed at two levels: decreased translation and decreased mRNA stability. 
Results
Effect of Rapamycin on the production of IL-2 by activated T cells. It has been reported that IL-2 signaling in activated T cells is rapamycin sensitive, whereas IL-2 production is rapamycin insensitive 31, 32 . Other reports show that IL-2 production by activated T cells is sensitive to rapamycin 43, 44 . To investigate the effect of rapamycin on the IL-2 production by activated T cells, we used freshly isolated human peripheral blood T cells. As shown in Fig. 1a , T cells stimulated with cross-linked CD3 and CD28
produced a significant amount of IL-2, and this production was suppressed significantly by the pre-treatment of the cells with rapamycin.
Previous studies have shown that the immunosuppressive drug CsA drastically inhibits, but does not completely block, IL-2 production following stimulation with CD3 and CD28 4 . The drug resistant activity can most likely be traced to the CD28 signaling pathway, since stimulation of cells with PMA (to mimic Ca 2+ -independent aspects of CD3 signaling) and CD28 is entirely resistant to CsA. On the other hand, the CsA-sensitive pathway can be mimicked by stimulation with PMA and ionomycin 4 . We wanted to know whether the immunosuppressive properties of rapamycin were due to the inhibition of CsA-resistant pathway. Peripheral blood T cells were stimulated either with PMA plus CD28 or PMA plus ionomycin in the presence or absence of either CsA or rapamycin. As shown in Fig. 1b and c, PMA/ CD28 was a weaker stimulus to IL-2 production; however, CsA had minimal effect on PMA/ CD28 stimulation, whereas this treatment completely blocked PMA/ionomycin-mediated IL-2 production. In contrast, only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From rapamycin significantly inhibited PMA/ CD28-induced IL-2 production, whereas it did not have any effect on PMA/ionomycin stimulation. Similar effects were also observed at lower dose of rapamycin (10 ng/ml) (data not shown). These data suggest that rapamycin alters IL-2 production by activated T cells, and this suppressive effect is mediated by the sensitivity of the CsA-resistant CD28 co-stimulatory pathway to rapamycin.
Since the effect of rapamycin has been reported to be due to blocking IL-2 signaling, it was important to demonstrate that no IL-2 signaling was involved in the suppressive effect of rapamycin on the CsA-resistant CD28 co-stimulatory pathway.
We decided to use a sensitive assay to monitor the involvement of IL-2 signaling. We performed EMSA using the consensus Stat-binding site from the Fc RI promoter to detect Stat 5 and , two IL-2-specific Stats 45, 46 . As shown in signaling. These data suggest that the effect of rapamycin on PMA/ CD28-mediated signaling was not due to the blockage of IL-2 signaling.
Rapamycin affects PMA/CD28-mediated IL-2 message stability. To determine whether the effect of rapamycin on IL-2 production was transcriptional or posttranscriptional, we performed northern blot analysis using total RNAs. T cells were stimulated with PMA/ CD28 in the presence or absence of rapamycin for various periods of times, and total RNAs were isolated and were analyzed by northern blot analysis. As shown in Fig. 3a , IL-2 message was detected as early as 2 hrs, peaked about 6 hrs, and stayed at high levels for at least 24 hrs. Interestingly, pretreatment with rapamycin did not alter the induction of IL-2 message at the earlier time points, although this treatment did suppress the mRNA level at 24 hrs. Fig. 3b shows the graphical representation of the IL-2 mRNA levels quantitated and normalized with the 18S ribosomal RNA. These data suggest that rapamycin did not have any effect on IL-2 gene transcription. We tested the effect of rapamycin on the transient transfection assay using an IL-2 promoter-reporter construct. Rapamycin did not affect PMA/ CD28-mediated promoter activity (data not shown), which is in agreement with the recent report by Kane et al. 48 . Therefore, rapamycin does not act at the level of the IL-2 promoter. To examine the differential effect of rapamycin on PMA/CD28-versus PMA/ionomycin-induced IL-2 mRNA levels, peripheral blood T cells were stimulated with either medium alone, only.
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Total RNAs extracted from activated T cells were analyzed by northern blot analysis. As shown in Fig. 3c , PMA/ CD28-induced IL-2 mRNA level was reduced by rapamycin pretreatment (compare lane 3 with 2), whereas rapamycin did not have any effect on PMA/ionomycin-induced IL-2 mRNA level (lane 5 vs 4). The difference in the IL-2 mRNA levels between PMA/ CD28 versus PMA/ionomycin stimulation reflects the difference in the IL-2 production by these two sets of stimuli (Fig. 1b & c) .
Next we wanted to test the effect of rapamycin on IL-2 mRNA stability.
Peripheral blood T cells were treated with PMA/ CD28 in the presence or absence of rapamycin for 18 hr. At 18 hr. actinomycin D was added to the culture to stop new RNA synthesis, and cells were incubated further for either 1.5 or 3 more hrs. At each time point, cells were collected and RNAs were isolated for northern blot analysis. As shown in Fig. 3d , PMA/ CD28-induced IL-2 mRNA was fairly stable throughout the time of actinomycin D treatments (lanes 1-3) . In contrast, addition of rapamycin caused rapid degradation of IL-2 message (lanes 4-6). These data suggest that the effect of rapamycin on PMA/ CD28-mediated IL-2 production was med iated by increasing the turnover of IL-2 mRNA.
Effect of rapamycin on the phosphorylation status of 4EBP-1. It has been well established that mTOR, the target of rapamycin, plays an important role in translation 34 .
One of the important components in translation that is directly regulated by mTOR is 4EBP-1, a repressor of eukaryotic initiation factor 4E (eIF4E), whose phosphorylation only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From status dictates the initiation of translation 35 . To examine the effect of PMA/CD28 stimulation on the phosphorylation status of 4EBP-1, peripheral blood T cells were stimulated with PMA/ CD28 for various periods of time, and the whole cell lysates were analyzed by western blot analysis using an antibody specific for phospho-4EBP-1 which is phosphorylated on Ser-65. As shown in Fig. 4 , multiple phosphorylated forms of 4EBP-1 were observed as early as 3 hr. after stimulation, and the amount of phosphorylated proteins increased with time. Pre-treatment of these cells with rapamycin caused the dephosphorylation of 4EBP-1, and this effect of rapamycin was observed as early as 3 hrs. The effect of rapamycin was specific to PMA/CD28 stimulation, since PMA/ionomycin-induced multiple phosphorylated forms of 4EBP-1 were unaffected by rapamycin (data not shown). These and the data presented above demonstrate that rapamycin inhibits PMA/ CD28-mediated IL-2 production by two mechanisms: first, decreased translation of IL-2, which is the earliest effect, and second, decreased mRNA stability, which is the later effect.
Effect of rapamycin on PMA/CD28-mediated JNK-1 activity. To determine the signaling pathways involved in the rapamycin-mediated IL -2 message instability, we examined PMA/ CD28 induced JNK-1 activity. JNK-1 has been shown to play an important role in IL-2 mRNA stability in activated T cells 49 . Human peripheral blood T cells were stimulated with PMA/ CD28 for various periods of time. Whole cell lysates were prepared and the immunocomplex kinase assay was performed according to the protocol described in Materials and Methods. As shown in Fig. 5a , PMA/ CD28 treatment induced kinase activity as early as 15 min, peaked around 30 min. and only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From maintained a high level of activity for at least 24 hr. Interestingly, pretreatment of rapamycin suppressed JNK-1 activity at 24-hr time point (Fig. 5a, upper panel) . The inhibition of JNK activity was not due to the difference in JNK protein level, since rapamycin treatment did not alter the JNK level (Fig. 5a, lower panel) 2) . These data reinforce the fact that rapamycin only blocks the CsA -resistant pathway of CD28 costimulation.
Previously it has been shown that PMA/ CD28 stimulation also activates p38
MAP kinase 18 . To examine whether p38 plays any role in IL-2 mRNA stability, we tested the effect of rapamycin on the PMA/ CD28-induced p38 by western blot analysis only.
For (Fig. 5d) . The phospho-p38 was induced as early as 3 hours and was present at the same levels for at least for 24 hrs. Interestingly, this induction was unaffected by rapamycin pre-treatment. These data indicate the involvement of JNK-1, but not p38 in the PMA/ CD28-mediated IL-2 message stability. 2). These data suggest that rapamycin-induced blockage of JNK-1 activity was mediated by PP2A/PP1. To check whether the reversal of JNK-1 inhibition by okadaic acid was reflected in the IL-2 mRNA stability, northern blot analysis was performed using RNAs isolated from the same experiment as described in Fig. 6a . Like the JNK assay, the suppression of PMA/ CD28-induced IL-2 message by rapamycin was reversed by simultaneous treatment with okadaic acid (Fig. 6b, lanes 5 vs 3) , whereas okadaic acid treatment alone did not alter PMA/ CD28-induced IL-2 mRNA level (Fig. 6b, lanes 4 vs   2) . Fig. 6c shows the IL-2 mRNA levels quantitated and normalized with 18S ribosomal 
Role of

Discussion
Rapamycin treatment of T cells inhibits IL-2 signaling, and blocks T-cell proliferation 31, 32 . In this report we demonstrate that rapamycin also blocks the production of IL-2 by activated human peripheral blood T cells. This effect of rapamycin was not accounted for by autocrine IL-2 signaling for the following reasons: first, we could not detect any Stat5, an IL-2-specific Stat, in PMA/ CD28-treated nuclear extracts in super shift assay, although stat5 was easily detected in the IL-2-treated nuclear extract (Fig. 2b) ; second, if IL-2 signaling was involved in the PMA/ CD28 treatment, then
PMA/ionomycin treatment also should have been effected by rapamycin, but this stimulation was unaffected even though a much higher level of IL-2 was produced by PMA/ionomycin treatment (Fig. 1b & c ) . The data presented here suggested that the treatment of rapamycin blocked IL-2 production in a pathway-specific manner.
Previous studies have shown that the activation of T cells with CD3 plus CD28 triggers pathways that are broadly classified into two groups: one is calcium-dependant and sensitive to CsA, and the other one is calcium-independent and resistant to CsA 10 .
The CsA-resistant pathway has been thought to be responsible for the ineffectiveness of CsA in the treatment of graft versus host disease following allogenic bone marrow transplantation 39 . To study these pathways separately one can stimulate T cells either with PMA and CD28 to mimic the CsA-resistant pathway, or with PMA and ionomycin to activate the CsA-sensitive pathway. The data presented here demonstrate that only.
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One of the first signaling molecules involved in CD28 signaling was shown to be PI3-K [11] [12] [13] . Recently, it has been shown that the serine-threonine kinase Akt, a target of PI3-K, can provide some of the CD28 co-stimulatory signals, e.g., production of IL-2 and IFN-, but is unable to restore the production of IL-4 or IL-5 by CD28-deficient mice 50 .
Interestingly, expression of activated Akt in CD28-deficient mice was also unable to restore the proliferative response to secondary stimulation 50 . These authors also reported, but data were not shown, that rapamycin did not effect Akt-mediated IL-2 promoter activation. mTOR, the target of rapamycin, has been shown to lie downstream of Akt in different cell types including T cells 31, 52 . Since rapamycin inhibited IL-2 production by activated T cells, we wanted to know whether the effect of rapamycin was transcriptional or post-transcriptional. The northern blot analysis presented here suggested that rapamycin did not have any effect on the transcription of the IL-2 gene, because the effect of rapamycin was not observed until 18 to 24 hrs, whereas IL-2 message was detected as early as 2 hrs (Fig. 2a) . The effect of rapamycin on IL-2 transcription was also verified by the transient transfection studies using IL-2 promoter reporter constructs (data not shown). Our data are in agreement with Kane et al. 48 in that rapamycin does not act at the level of the IL-2 promoter. The data presented in Fig. 2c demonstrated that the effect of rapamycin was on PMA/ CD28-mediated IL-2 mRNA stability. These data put mTOR downstream of Akt in PMA/ CD28 signaling in only.
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It has been well established that mTOR is a key regulator of translation 34 , and 4EBP-1 is a downstream target molecule whose phosphorylation status dictates the initiation of translation 35 . The availability of the initiation factor eIF4E is critical for the initiation of translation, and is dependent on the phosphorylation status of 4EBP-1.
Hypophosphorylated 4EBP1 binds to eIF4E, whereas hyperphosphorylation abrogates this interaction 36 . We demonstrate here that the phospho-4EBP-1 induced by PMA/ CD28 treatment was found to be dephosphorylated by rapamycin pretreatment as early as 3 hr after exposure (Fig. 4) . These data suggested that the earliest effect of rapamycin on PMA/ CD28-mediated IL-2 production might be due to the blockage of IL-2 translation.
The role of JNK in IL-2 message stability has been well documented 49 . We demonstrate here that JNK also plays an important role in CsA-resistant PMA/ CD28-mediated IL-2 mRNA stability. JNK has been shown to be activated by PMA/ CD28 via activation of vav and Rac, and this activation of JNK is CsA-resistant 18, 19 . We demonstrate here that the PMA/ CD28-mediated JNK-1 activation is sensitive to rapamycin. Interestingly, the rapamycin effect on JNK-1 activity was not observed until 18 hrs, although the kinase activity was detected as early as 15 min (Fig. 5a ). These data along with the fact that rapamycin had no effect on PMA/ CD28-mediated IL-2 transcription suggested that JNK-1 might be involved in PMA/ CD28-induced IL-2 only.
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PMA/ CD28 stimulation also activated p38, but that activation was not sensitive to rapamycin treatment indicating specific involvement of JNK-1 in PMA/ CD28-mediated IL-2 mRNA stability. The role of JNK-1 in IL-2 mRNA stability was further demonstrated by the fact that the treatment with okadaic acid, which reversed the rapamycin-mediated suppression of JNK-1 activity, also blocked the rapamycin-mediated suppression of IL-2 message (Fig. 6a & b) . These data suggest the involvement of PP2A/PP1 in the suppression of PMA/ CD28-induced JNK-1 activity upon rapamycin treatment. Indeed, a similar phenomenon has been reported in the regulation of 4EBP-1 and p70 s6k by PP2A during amino acid deprivation 51 . In that study, the authors reported the activation of PP2A upon inhibition of mTOR by rapamycin. The inhibition of JNK-1 activity by rapamycin also suggests a linear pathway that includes of mTOR and JNK-1.
But that may not be the case for the following reason: rapamycin-mediated suppression of mTOR may be responsible for the activation of PP2A/PP1, which in turn inhibits JNK-1 activity. To be in the same linear pathway with JNK-1, mTOR must be active in the presence of rapamycin. It is known that mTOR kinase activity is blocked by rapamycin.
Thus, it is possible that JNK-1 activated by the vav/Rac pathway becomes the target of rapamycin-induced PP2A/PP1 (Fig. 7) . This could also explain why the inhibition of JNK-1 activity by rapamycin is a late event.
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The inhibitory effect on IL-2 signaling and subsequent blockage in T cell proliferation by rapamycin has been well documented 31, 32 , and because of its immunosuppressive property, rapamycin has been approved for clinical use along with other immunosuppressants 33 . The data presented here regarding the inhibition of IL-2 production by rapamycin provides additional information on the mechanism of action of rapamycin in activated T cells. It will be of great interest to identify the physiologically relevant pathways that mimic the PMA/ CD28-mediated CsA-resistant pathway, and to examine these pathways for their sensitivity to rapamycin. Indeed, IL-12 has been shown to synergize with CD28 in a CsA-resistant manner 53 . The effect of rapamycin on this pathway is currently under investigation. Investigating the effect of rapamycin in vivo in the presence or absence of CsA on the differentiation of T helper cells and on the development of GVHD could greatly enhance our ability to perform allogeneic stem cell transplantation more safely.
For and with IL-2 (100 units/ml; lane 8) were also used in the EMSA. 
